MARKET

COLL

COLL

Collegium Pharm
NASDAQ

Real-time Quotes | Nasdaq Last Sale

18.30
+0.66
+3.74%
After Hours: 18.30 0 0.00% 16:00 04/08 EDT
OPEN
18.04
PREV CLOSE
17.64
HIGH
18.88
LOW
17.62
VOLUME
481.94K
TURNOVER
--
52 WEEK HIGH
25.59
52 WEEK LOW
10.01
MARKET CAP
623.13M
P/E (TTM)
-26.9197
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 9 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average COLL stock price target is 33.57 with a high estimate of 38.00 and a low estimate of 24.00.

EPS

COLL News

More
  • Collegium to Participate in Upcoming Investor Conference
  • GlobeNewswire · 1d ago
  • Top Ranked Growth Stocks to Buy for April 6th
  • Zacks · 2d ago
  • Top Ranked Growth Stocks to Buy for April 1st
  • Zacks · 04/01 13:50
  • Collegium: Unjustified Sell-Off Alters My Plans
  • Seeking Alpha - Article · 03/30 13:21

Industry

Pharmaceuticals
+2.78%
Pharmaceuticals & Medical Research
+2.83%

Hot Stocks

Symbol
Price
%Change

About COLL

Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company. The Company is engaged in developing and commercializing abuse-deterrent products that incorporate its DETERx platform technology for the treatment of chronic pain and other diseases. Its products include Xtampza ER and ONSOLIS. Its DETERx platform provides extended-release drug delivery, while safeguarding against common methods of abuse and tampering, including crushing, chewing, and heating and injecting. Xtampza ER is designed to provide adequate pain control while maintaining its extended-release drug release profile after being subjected to common methods of abuse and accidental misuse. ONSOLIS is a Transmucosal Immediate-Release Fentanyl (TIRF) film indicated for the management of breakthrough pain in cancer patients (BTPc), 18 years of age and older, who are already receiving and who are tolerant to opioid therapy for their underlying persistent cancer pain.
More

Webull offers kinds of Collegium Pharmaceutical Inc stock information, including NASDAQ:COLL real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, COLL stock news, and many more online research tools to help you make informed decisions.